Table 3.
DESS evaluated | Tregs | Bregs | ||
---|---|---|---|---|
Clinicopathological Characteristic | r | P | r | P |
Weight Loss | -0.339 | 0.043* | - | - |
HBV Infection History | 0.360 | 0.031* | - | - |
Leucocyte | 0.363 | 0.029* | - | - |
Hepatitis B e Antigen | - | - | 0.527 | 0.030* |
HBV DNA Copy number | - | - | 0.532 | 0.028* |
Ferritin | -0.451 | 0.006** | - | - |
Numbers of up-regulated tumor markers # | -0.376 | 0.024* | - | - |
Portal vein tumor thrombosis | -.408* | 0.014* | - | - |
Hepatic vein invasion | -.413* | 0.012* | - | - |
BCLC score | -0.443 | 0.007** | - | - |
TNM stage(AJCC) | -0.347 | 0.038* | - | - |
(*, ** stands for P < 0.05, 0.01, respectively)
# Tested tumor markers:α-fetoprotein; cancer antigen 125; cancer antigen 153; cancer antigen 199; Ferritin; Carcino-embryonic antigen; prostate specific antigen.
HCC: Hepatocellular carcinoma; Tregs: Regulatory T cells; Bregs: Regulatory B cells; HBV: Hepatitis B virus; BCLC: Barcelona Clinic Liver Cancer Staging System; TNM (AJCC): Tumor-Node-Metastasis Staging System (American Joint Committee on Cancer).